Cabozantinib targets bone microenvironment modulating human osteoclast and osteoblast functions

Cabozantinib, a c-MET and vascular endothelial growth factor receptor 2 inhibitor, demonstrated to prolong progression free survival and improve skeletal disease-related endpoints in castration-resistant prostate cancer and in metastatic renal carcinoma. Our purpose is to investigate the direct effe...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Fioramonti, Marco, Santini, Daniele, Iuliani, Michele, Ribelli, Giulia, Manca, Paolo, Papapietro, Nicola, Spiezia, Filippo, Vincenzi, Bruno, Denaro, Vincenzo, Russo, Antonio, Tonini, Giuseppe, Pantano, Francesco
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2017
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5386748/
https://ncbi.nlm.nih.gov/pubmed/28223547
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.15390
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky